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Summary
Studies of radioresistance and radioprotection provide an excellent in vivo model for dissection
ofthe pathophysiological role ofcytokines . The availability ofneutralizing antibodies to cytokines
has made it possible to assess the contribution of cytokines to host defense and repair processes
involved in radioresistance and radioprotection. Administration of anti-interleukin 1 receptor
(IIAR) antibody (35F5) or anti-tumor necrosis factor (TNF) antibody (TN3 19 .12) reduced
survival of irradiated CD2F1 mice. These results demonstrate conclusively that natural levels
of Ilrl and TNF contribute to radioresistance of normal mice . Furthermore, the radioprotective
effect of administered IL1 was blocked not only with anti-IIr1R antibody but also with anti-
TNF antibody. Similarly, the radioprotective effect ofTNF was reduced with anti-IIAR antibody.
These data suggest that cooperative interaction of both cytokines is necessary to achieve successful
radioprotection . Finally, when LPS was used as a radioprotector, the combined administration
ofanti-IIAR and antiTNF not only blocked the radioprotection with LPS, but actually revealed
LPS to have a radiosensitizing effect . This effect may be due to induction of TGF-a, since
administration of this cytokine results in reduced survival of irradiated mice.
T
he lethal effects of whole-body exposure to ionizing radi-
ation are due primarily to the destruction of hemato-
poietic components and subsequent failure of hematopoietic
renewal (1, 2) . The use of immunostimulatory/inflammatory
agents such as LPS before irradiation was shown more than
30 years ago to promote survival from otherwise lethal doses
of radiation with subsequent recovery of the hematopoietic
system (3, 4) . It is nowknown that many of the pathophysio-
logical in vivo effects ofUS are mediated through the in-
duction of a battery of cytokines, including ILl and TNF.
We, therefore, hypothesized and established that these two
cytokines can confer radioprotection (5, 6) . The combined
administration of the two cytokines had a synergistic radi-
oprotective effect and was more effective than administration
of an optimal dose of LPS (6) .
In addition to induction by LPS, IIr1 and TNF areknown
to be produced in response to stress, infectious agents, and
a variety of inflammatory stimuli (7, 8) . Most recently, ILl
1177
￿
The Journal of Experimental
andTNF production was shown to be induced after exposure
to ionizing radiation (9, 10) .
These observations led us to ask several questions . First,
do endogenously produced I1J1 and TNF contribute to the
enhanced radioresistance of normal mice? Second, do IIr1 and
TNF act independently or cooperate in radioprotection? And
third, do IL1 and TNF account for the entire radioprotec-
tive effect of LPS? The results reported here provide evidence
that IIr1 and TNF are essential for natural as well as for
immunomodulator-enhanced radioresistance.
Materials and Methods
Mice
￿
CD2F1 male andC3H/HeN female mice were purchased
from the Animal Genetics and Production Branch, National Cancer
Institute (Frederick, MD) . C3H/Hej female mice were obtained
from The Jackson Laboratory (Bar Harbor, ME) . Mice were han-
dled as previously described (6) .
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Recombinant human ILlcx (rhI1r1a)' (117-271 Ro
24-5008; lot IIrl 2/88 ; sp act 3 x 108 U/mg) waskindly provided
by Dr. Peter Lomedico, Hoffmann-La Roche Inc . (Nutley, NJ) .
Recombinant human TNF-a (rhTNF-ac) (lot CP4026P08 in PBS ;
sp act 9.6 x 106 U/mg protein) was obtained from Biogen (Cam-
bridge, MA), and recombinant murine TNF-a (rmTNF-a) (lot
4296-17 ; sp act 2 x 10 8 U/mg, as assayed on 1,929 cells in our
laboratory)was kindlyprovidedby Genentech (San Francisco, CA) .
TGF-/3 (lot 8987-53) was kindly providedby Dr. Palladino ofGenen-
tech . LPS (protein-free prepared from Escherichia coli K235 by the
phenol-water extraction method)was kindly provided byDr. Stefanie
Vogel of Uniformed Services University for the Health Sciences
(Bethesda, MD).
Antibodies.
￿
Anti-IDIRantibody,mAb 35F5,was raised in rats
against cloned IL1R isolated fromEL 4 cells as previously described
(11) . Anti-murine TNF antibody, mAb TN3.19.12, was raised in
Armenian hamsters against murineTNF-a as previously described
(12) . Rat Ig (Sigma Chemical Co., St . Louis, MO) was used as
a control for 351`5 antibody. As controls forTN3.19.12, anti-mu-
rine IFN-yantibody (H22, an antibody raised in hamsters against
murine IFN-y) or hamsterIgG (1,2.3139 raised in Armenian ham-
ster against human 11,2, as described [12]) were used .
The antibodies and recombinant rytokines were diluted in
pyrogen-free saline on the day of injection. The antibodies were
given intraperitoneally 6-20 h before intraperitoneal injection of
the rytokines.
Irradiation.
￿
Mice were randomized, placed in Pletiglass con-
tainers, and were given whole-body irradiation at 40 cGy/min by
bilaterally positioned 6°Co elements. The number of surviving
mice was recorded daily for 30 d.
StatisticalAnalysis .
￿
Statistical evaluation ofthe results was car-
ried out using XZ analysis and Cox Mantel test .
Results
The Role ofIL1 and TNF in Natural Radioresistance
￿
To
test whether endogenously produced ILl andTNF contribute
to the natural radioresistance ofnormal mice, mice were treated
with anti-111R antibody, which blocks the activities ofboth
ILla and IL1O (11), or with antiTNF antibody (12) . Ad-
ministration of anti-ILIR antibody (351`5) or antiTNF an-
tibody (TN3 19.12) to LD4oi3o irradiated mice reduced their
survival (Fig . 1) . The apparent radiosensitizing effect observed
in normal mice given either antibody 20 h before irradiation
was equal to that observed in mice given the antibody 1 h
after irradiation. Thus, these antibodies exacerbate radiation
damage by blocking the beneficial effects of rytokines even
when produced after the completion of radiation exposure.
Do ILI and TNF Act Independently or Cooperate in Radio-
protection? 1171 andTNF are well documented to induce one
another in vitro (13-16) . We examined the interdependence
of IL -1 and TNF in radioprotection by testing the effect of
neutralization of TNF in IL1-injected mice and receptor
blockage of IL1 in TNF-injected mice (Fig . 2) . Anti-ILIR
antibody, givento mice before TNFadministration, reduced
the proportion of TNF-radioprotected mice from 60% to
15%. Similarly, anti-TNF antibody reduced 11,1-induced ra-
dioprotection from 88% to 40%. These in vivo results show
I Abbreviations used in this paper . rh, recombinant human ; rm, recombinant
murine.
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Figure 1 .
￿
Radiosensitizing effect ofanti-11,1R antibody (35F5) and anti-
TNF antibody (TN3 19.12.) . CD2F1 male mice 8-10 wk old received
intraperitoneal injections of 100pg 35F5, 20 h before or 1 h after irradia-
tion with 825 cGy 6OCo. TN3 19.12 antibody was given at 100 lAg 20 h
before irradiation or at 50 pg 1 h after irradiation. Groups of control mice
were given 100 Ag ofrat IgG, 100 t~g anti-murine IFN-y, or 1001`g of
hamster IgG, or vehicle-saline injection of0.5 ml per mouse.The survival
of mice given 825 cGy was recorded daily for 30 days . The survival time
of control mice receiving anti-IFN-y, rat IgG, or hamster IgG did not
differ from mice given saline injections (at 66, 50, and 68%, respectively ;
not shown in the figure) . The survival of mice receiving 351`5 or TN3
19.12 before or after irradiation was significantly different from that of
control mice (p<0.01) . (')Thenumber ofmice used in the experiments .
that TNF contributes to optimal radioprotection with IIA,
and that IL1 participates in radioprotection with TNF .
Do ILI and TNF Accountfor the Entire Radioprotective Elect
ofLPS?
￿
Therelative contribution of IL-1 andTNF in LPS-
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Figure 2.
￿
Anti-IIAR antibody (351`5) reduces TNF-inducedradioprotec-
tion, and antiTNF antibody (TN319.12) reduces IIA-induced radioprotec-
tion . CD2F1 mice received intraperitoneally 100 Rg of 351`5 or 200 wg
ofTN3 19.12 . Groups of control mice received injections of equivalent
amounts of rat IgG or hamster IgG (L2.3D9) or saline injections . 20 h
later, groups of mice received either 300 ng rhIIr1, 5 1`,g of rhTNF-a,
or 1 1`.g of miTNFot . After an additional 20 h, mice received 950 cGy
of6OCo radiation . The survival time was recorded for 30 d . The survival
ofmice receiving rhTNF or rmTNFwas similar and the groups were there-
fore combined. Control mice receiving rat IgG or hamster IgG and IIA
did not differ significantly in survival from IIrl only-treated mice (at 80
and95%, respectively) . 65% ofmice given hamster IgG beforeTNF sur-
vived. The numbers at the top of the bars indicate the total number of
mice used in eight experiments. The survival of mice receiving 351`5 and
IIA orTN3 19.12 and ILl differed significantly (p <0.01) from survival
ofmice receiving 11,1 alone. Similarly, the survival ofmice receiving 351`5
andTNF differed significantly (p<0.01) from that ofmice receivingTNF
alone.induced radioprotection was investigated using neutralizing
antibodies. Anti-IIAR antibody given to mice before LPS
and lethal irradiation reduced survivalfrom 74% to 20% (Table
1) . Similarly, antiTNF antibody given before LPS reduced
survival to 30%. Combined administration ofthese antibodies
completely abolished the radioprotective effect ofLPS, demon-
strating that this effect is due entirely to the combined effect
of IIrl and TNF. Furthermore, administration of both anti-
bodies actually led to a reduced survival time ofLPS-treated
mice to less than that of nontreated mice (Figure 3) . Thus,
inhibition of IIrI- and TNF-mediated effects ofLPS revealed
LPS to have latent radiosensitizing capabilities .
The Effect o,f TGF-,B on Survival ofIrradiated Mice.
￿
Based
on the above observations, we asked whether some of the
cytokines induced by LPS may contribute to increased radia-
tion lethality. LPS induces secretion ofTGF-0 from human
blood monocytes (17) . We tested the radiosensitizing effect
of TGF-0 because of its previously observed activity of in-
hibiting proliferation of early bonemarrow progenitor cells,
and of inhibiting many of the biologic effects of IIA and
TNF (18-22) . Indeed, TGF-0 given to mice either before or
after lethal irradiation resulted in a dose-dependent reduc-
tion in survival (Fig . 4) .
TGF-0 was also radiosensitizing for C3H/HeJ and
C3H/HeN mice. 85% (17/20) of control C3H/HeN mice
survived 725 cGy radiation, whereas only 10% (1/10) ofmice
given 10 jig TGF-/316 h before, and 15% (3/20) givenTGF-0
1 h after irradiation, survived. Similarly, none oftheC3H/HeJ
mice given 10 leg TGF-0 1 h after irradiation with an
LD5oi3o survived . Thus, the sensitizing effect of TGF-0 to
radiation lethality is not restricted to a particular mouse strain.
Combined administration of ILA and TGF-(3, however, did
Table 1.
￿
Effect ofAnti-IL-1 Antibody and Anti-TNF Antibody
on LPS-induced Radioprotection
CD2F1 mice received intraperitoneally 200 Ag anti-IL-1R, 200 ug anti-
TNF, or both . Groups of control mice received 200,ug hamster IgG, rat
IgG, or saline injections. 20 h later, mice received 1 hg E . Coli LPS in-
traperitoneally, and 1 d later were given 950cGygamma radiation . The
survival time was recorded for 30 d . The survival of mice in groups 5
and6 was significantly reduced (p<0.01) compared with survival ofmice
in groups 2, 3, and 4. There wasno significant difference in the survival
of groups 2, 3, and 4 .
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Figure3.
￿
Effect of anti-IIr1R antibody and antiTNFantibody on LPS-
induced radioprotection . Groups of mice received treatment as described
in Table 1. The daily record of survival of mice given a combination of
200 t~g of 35F5 and 200 itg of TN3 19.12 antibody and LPS, LPS alone,
or saline control and 950 cGy irradiation is presented . The mean survival
time ofLPS- and antibody-treated mice was significantly reduced as com-
pared with the control mice (p < 0.001 using Cox Mantel test) .
not result in any reduction of the radioprotective effect of
IIr1 (results not shown), indicating that the presence ofIM
masks the radiosensitizing effects of TGF-(3 .
Discussion
Cytokines have beenshown to have somany complex effects
that it has become virtually impossible to predict their rele-
vant role from the in vitro models. Consequently, it is more
imperative than ever to evaluate their pathophysiological role
in vivo. Studies of the role of cytokines in counteracting the
lethal effects of radiation provide a useful model for evalu-
ating the in vivo role of these cytokines in promoting the
restoration of hematopoiesis and consequent enhancement of
host resistance to infections. Our results showing that greater
number of mice receiving anti-IIAR antibody or antiTNF
antibody die after exposure to ionizing radiation indicate that
endogenously produced IIrl and TNF play an important role
in the host's ability to recover from lethal radiation . The
specificity of anti-IIAR antibody was previously demonstrated
100
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Figure 4.
￿
Radiosensitizing effect of TGF-0. CD2F1 mice received in-
traperitoneal injections of rhTGF-0 at times before and after irradiation
in quantities as indicated, or saline injection.The results are a summary
ofthree experiments. The survival of mice receiving 10,ugTGF-0 before
or after irradiation differ significantly (p<0.001) from that of saline-treated
mice.
Group LPS
Treatment
Antibody
Dead/
total
Percent
survival
1 - Saline 56/59 5
2 + Saline 16/61 74
3 + Rat IgG 12/36 67
4 + Hamster IgG 3/18 83
5 + Anti-IL-1R 24/30 20
6 + Anti-TNF 14/20 30
7 + Anti-IL-1R-anti-TNF 20/20 0since passive immunization of mice with 351`5 antibody re-
duced IIL1-induced radioprotection, and also reduced ILl-
induced serum levels of 11,6, CSF, and serum amyloid P (23,
24) . Similarly, administration of antiTNF antibody, TN3-
19.12, to mice subsequently treated with LPS specifically
prevented the appearance ofTNF in the circulation (12) . Serum
levels of351`5 and TN3 19.12 were previouslyshown to pla-
teau within 6-8 h and to remain elevated for 2-7 d after in-
jection (11, 12) . Thus, the data showing that administration
of antibody after irradiation has an effect similar to antibody
given before irradiation suggest that radiation-induced IL1
and TNF confer radioresistance by promoting repair and
restoring host defenses after lethal radiation damage. This
effect ofendogenously producedIW andTNF is augmented
by administration of an exogenous supply of these cytokines,
as previously observed (5, 6, 25) .
Our observation that anti-IIL1R antibody largely blocks
TNF-induced radioprotection whereas antiTNF antibody par-
tially blocks IILl-induced radioprotection suggests that mutual
induction of ILl by TNF and TNF by IL1 occurs in vivo
as well as in vitro (13-16), and their subsequent interaction
is necessary to achieve optimal radioprotection. This is in agree-
ment with a report by Dinarello et al . (26) demonstrating
that the second pyrogenic phase induced by supernatants from
TNF-stimulated mononuclear cells could be neutralized by
anti-ILl antibody. We have also observed that the levels of
CSF induced in circulation after challenge with ILl can be
reduced by antiTNF antibody, whereas TNF-induced CSF
is reduced by anti-IL1R antibody (Neta et al ., unpublished
results) . Consequently, mutual induction of TNF and ILl
may be required not only for achieving in vivo radioprotec-
tion, but also for other in vivo effects . The generally observed
overlapping activities of IL1 and TNF (27, 28) may reflect
a cellular requirement for triggering by both signals, and ad-
ministration of either IIr1 or TNF alone would result in the
production of the necessary second signal ; thus accounting
for their apparent ability to act by themselves.
LPS is known to induce a battery of cytokines, including
ILl, TNF, CSF, IL6, 11,8, IFN, and TGF-(3 (29-33) . We
have previouslyshown that granulocyte CSF, granulocyte/mac-
rophage CSF, and 11,6, when administered together with
suboptimal doses of 114, synergize in radioprotection (6, 36) .
However, the present results indicate that neutralization of
TNF and ILl not only completely blocks the radioprotec-
tive effect ofLPS but also unexpectedly reveals LPS to have
radiosensitizing properties. Since administration of TGF-0
results in greatly enhanced mortality of irradiated mice, and
LPS is a known inducer of TGF-/3, we assume that in the
absence ofIL1 andTNF, other LPS-induced cytokines, IL6,
granulocyte CSF, or granulocyte/macrophage CSF, cannot
prevent radiation induced lethality. The finding that when
given with IILl, TGF-/3 does not reduce ILl-induced radi-
oprotection, provides further support that IL1 is critical for
radioprotection. Whether the enhanced lethality observed due
to TGF-0 is the direct result of: (a) inhibiting proliferation
of early progenitor cells ; (b) impairment of IL1 and TNF
synthesis, as previously shown (34); or (c) reduction ofIIL1R
expression (35) remains to be established . It is possible that
other cytokines induced with LPS, in addition to TGF-0,
may also contribute to radiosensitization . Indeed, we have
previously shown that IIr6 given alone before irradiation acts
also as a radiosensitizer (36) .
In conclusion, the present results provide the firstdemon-
stration that : (a) the endogenously produced cytokines, ILl
and TNF, contribute to natural radioresistance ; (b) ILl and
TNF, even when given separately, interact with one another
to produce radioprotection ; (c) radioprotection with LPS de-
pends on induction of IL1 and TNF, since blocking the ac-
tivities of these two cytokines completely abolishes the ra-
dioprotective effect ofLPS; (d) in the absence of IIL1 andTNF,
LPS exerts a radiosensitizing effect ; and (e) TGF-/3 renders
mice more sensitive to radiation . Thus, LPS induces a mix-
ture ofradioprotective and radiosensitizing cytokines . These
cytokines also mediate the immunomodulating effects ofLPS .
Consequently, therapeutic use of selected cytokines may be
preferable to the use of exogenous immunomodulators such
as LPS, which induce mixtures ofcytokines capable ofcoun-
teracting each other's effects .
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